Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
If You Invested $10,000 in Johnson & Johnson 5 Years Ago, This Is How Much You Would Have Today
10:40am, Friday, 02'nd Sep 2022 The Motley Fool
The healthcare company has generated positive returns for investors without putting their portfolios at much risk.
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
10:20am, Friday, 02'nd Sep 2022 Zacks Investment Research
Style Box ETF report for QUS
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
10:20am, Friday, 02'nd Sep 2022 Zacks Investment Research
Style Box ETF report for IWX
3 Warren Buffett Stocks to Buy Hand Over Fist In September
09:06am, Friday, 02'nd Sep 2022 The Motley Fool
Riding the Oracle of Omaha's coattails has been a moneymaking strategy for more than 50 years!
Microsoft Is A Cash Cow Blue Chip: Here's When To Snap Up Shares
05:38pm, Wednesday, 31'st Aug 2022 Seeking Alpha
Microsoft's business is a juggernaut. Read more on when investors should snap up MSFT stock in light of a tighter Fed and falling market valuations.
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
04:53pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplasti
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
10:20am, Wednesday, 31'st Aug 2022 Zacks Investment Research
Style Box ETF report for VYM
Johnson & Johnson (JNJ) Stock Moves -0.35%: What You Should Know
09:45pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $162.43, marking a -0.35% move from the previous day.
Amgen (AMGN) Outperforms Industry Year to Date: What's Next?
03:22pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Why Bristol Myers Squibb Stock Is Slumping Today
06:25pm, Monday, 29'th Aug 2022 The Motley Fool
The drugmaker's next-generation blood thinner fails to impress in a mid-stage trial.
Bristol Myers (BMY) Announces Milvexian Phase II Study Results
03:48pm, Monday, 29'th Aug 2022 Zacks Investment Research
Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
01:00pm, Monday, 29'th Aug 2022 Zacks Investment Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
11:43am, Monday, 29'th Aug 2022 Zacks Investment Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
Should You Invest in the Vanguard Health Care ETF (VHT)?
10:20am, Monday, 29'th Aug 2022 Zacks Investment Research
Sector ETF report for VHT
